Effect of Low-dose Intravitreal Bevacizumab and Ranibizumab on Regression and Late Reactivation in Retinopathy of Prematurity in the Treatment-Naïve Eyes

Ophthalmol Retina. 2022 Apr;6(4):328-330. doi: 10.1016/j.oret.2021.12.016. Epub 2021 Dec 27.

Authors

Charles Zhang¹, Andrew L Reynolds², Andrew Beiter³, John H Lillvis¹, James D Reynolds¹

Affiliations

¹ Department of Ophthalmology, Ross Eye Institute, University at Buffalo, Buffalo, New York.
² Department of Ophthalmology, Ross Eye Institute, University at Buffalo, Buffalo, New York. Electronic address: alr23@buffalo.edu.
³ Department of Ophthalmology, West Virginia University, Morgantown, West Virginia.

PMID: 34968757
DOI: 10.1016/j.oret.2021.12.016

No abstract available

Keywords: ROP; bevacizumab; pediatrics; ranibizumab; retina.

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Bevacizumab / therapeutic use
Humans
Infant, Newborn
Intravitreal Injections
Ranibizumab* / therapeutic use
Retinopathy of Prematurity* / diagnosis
Retinopathy of Prematurity* / drug therapy

Substances

Angiogenesis Inhibitors
Bevacizumab
Ranibizumab